India halves drug approval timelines and removes pre-clinical approval requirement
Regulatory affairs teams at drug developers face 120–150 day approval clocks
Change
India reduced clinical trial approval timelines to 120–135 days, ensured marketing authorisations clear within 150 days, and removed the requirement for regulatory approval at the pre‑clinical stage.
Why it matters
Regulatory workloads must be completed on a much tighter clock, forcing faster dossier finalisation and earlier regulator engagement. Removing mandatory pre‑clinical approvals shifts regulatory scrutiny into clinical‑stage filings and post‑authorisation oversight, changing when compliance checks occur.
Implications
- — Regulatory affairs teams at pharmaceutical and biotech developers — must update submission calendars and prepare complete clinical and marketing dossiers immediately — because regulator reviews now finish within 120–150 days and failure to meet the compressed timetable will delay trial starts and market entry.
- — Clinical trial operations teams at sponsors and contract research organisations (CROs) — must compress site selection, ethics submissions, and trial‑start workflows now — or study initiation will slip relative to the regulator's accelerated review window, deferring enrolment and milestones.
Unlock the decision layer.
- Implications: What this forces you to change — operations, exposure, or compliance.
- Who is affected: Which roles, contracts, and obligations are exposed.
- What to watch: Binding deadlines and enforcement dates.
- Real-time alerts: Delivered the moment a binding change is published.
- Ask AI: Ask what this means for your specific role.
No credit card · 14-day trial · Active in seconds
Unlock the decision layer
Source
Economic Times
View on Economic Times